bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
Company profile
Ticker
TECH
Exchange
Website
CEO
Charles Kummeth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TECHNE CORP /MN/
SEC CIK
Corporate docs
Subsidiaries
Research and Diagnostic Systems Inc. • Bio-Techne China Co. Ltd • ProteinSimple Ltd. • Novus Biologicals, LLC • Bio-Techne Ltd. • Advanced Cell Diagnostics, Inc. • Exosome Diagnostics, Inc. • Asuragen, Inc. • Cyvek, Inc ...
IRS number
411427402
TECH stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
6 May 24
8-K
Bio-techne Releases Third Quarter Fiscal 2024 Results
1 May 24
8-K
Bio-techne Appoints DR. Judith Klimovsky to Board of Directors
30 Apr 24
10-Q
2024 Q2
Quarterly report
7 Feb 24
8-K
Bio-techne Releases Second Quarter Fiscal 2024 Results
1 Feb 24
8-K
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
8 Jan 24
10-Q
2024 Q1
Quarterly report
7 Nov 23
8-K
Bio-techne Releases First Quarter Fiscal 2024 Results
31 Oct 23
8-K
Bio-techne Appoints Kim Kelderman As Chief Executive Officer
19 Oct 23
ARS
2023 FY
Annual report to shareholders
13 Sep 23
Transcripts
TECH
Earnings call transcript
2024 Q3
1 May 24
TECH
Earnings call transcript
2024 Q2
1 Feb 24
TECH
Earnings call transcript
2024 Q1
31 Oct 23
TECH
Earnings call transcript
2023 Q4
8 Aug 23
TECH
Earnings call transcript
2023 Q4
8 Aug 23
TECH
Earnings call transcript
2023 Q3
3 May 23
TECH
Earnings call transcript
2023 Q2
2 Feb 23
TECH
Earnings call transcript
2023 Q1
1 Nov 22
TECH
Earnings call transcript
2022 Q4
7 Aug 22
TECH
Earnings call transcript
2022 Q3
4 May 22
Latest ownership filings
4
JOHN L HIGGINS
16 May 24
144
Notice of proposed sale of securities
14 May 24
4
Judith V Klimovsky
3 May 24
3
Judith V Klimovsky
3 May 24
4
Shane Bohnen
5 Apr 24
4
Roeland Nusse
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
William Geist
5 Feb 24
4
Matthew McManus
5 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
95.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 520 |
Opened positions | 163 |
Closed positions | 49 |
Increased positions | 158 |
Reduced positions | 131 |
13F shares | Current |
---|---|
Total value | 9.92 tn |
Total shares | 150.35 mm |
Total puts | 180.90 k |
Total calls | 171.20 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.27 mm | $1.29 tn |
BLK Blackrock | 17.75 mm | $1.25 tn |
STT State Street | 6.37 mm | $448.31 bn |
T. Rowe Price | 5.75 mm | $404.47 mm |
Bamco | 5.00 mm | $351.82 bn |
MS Morgan Stanley | 4.19 mm | $294.95 bn |
Geode Capital Management | 3.84 mm | $269.48 bn |
Neuberger Berman | 3.57 mm | $251.63 bn |
AMP Ameriprise Financial | 3.28 mm | $230.95 bn |
IVZ Invesco | 3.13 mm | $220.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 May 24 | Higgins John L | Common Stock | Sell | Dispose S | No | No | 83.8443 | 4,000 | 335.38 k | 36,608 |
14 May 24 | Higgins John L | Common Stock | Option exercise | Acquire M | No | No | 22.95 | 4,000 | 91.80 k | 40,608 |
14 May 24 | Higgins John L | Stock Options Common Stock | Option exercise | Dispose M | No | No | 22.95 | 4,000 | 91.80 k | 12,000 |
1 May 24 | Klimovsky Judith V | Common Stock | Grant | Acquire A | No | No | 0 | 680 | 0.00 | 680 |
1 May 24 | Klimovsky Judith V | Stock Option Common Stock | Grant | Acquire A | No | No | 73.46 | 1,610 | 118.27 k | 1,610 |
3 Apr 24 | Shane Bohnen | Common Stock | Payment of exercise | Dispose F | No | No | 67.87 | 747 | 50.70 k | 1,647 |
3 Apr 24 | Shane Bohnen | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,259 | 0.00 | 2,394 |
3 Apr 24 | Shane Bohnen | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,259 | 0.00 | 4,519 |
7 Mar 24 | Roeland Nusse | Common Stock | Sell | Dispose S | No | No | 76.9834 | 10,400 | 800.63 k | 43,097 |
News
Demystifying Bio-Techne: Insights From 4 Analyst Reviews
22 May 24
Citigroup Downgrades Bio-Techne to Neutral, Announces $85 Price Target
22 May 24
Molecular Instruments Announced The Patents Court Of England And Wales Has Ordered That Two Patents Owned By Advanced Cell Diagnostics, A Bio-Techne Company, Both Be Revoked, Advanced Cell Diagnostics' Infringement Claims Against Molecular Instruments Are Dismissed And Advanced Cell Diagnostics Make A Costs Payment Of ~$1.72M To Molecular Instruments
21 May 24
Which Large-Cap Stocks Are Winning This Earnings Season? 15 Stocks To Watch (April 28-May 4, 2024)
5 May 24
Benchmark Reiterates Buy on Bio-Techne, Maintains $95 Price Target
2 May 24
Press releases
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
23 May 24
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
22 May 24
Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments
21 May 24
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
8 May 24
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
7 May 24